708 related articles for article (PubMed ID: 27270107)
1. Clonal evolution of glioblastoma under therapy.
Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
[TBL] [Abstract][Full Text] [Related]
2. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Gao YT; Chen XB; Liu HL
Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
5. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Kim J; Lee IH; Cho HJ; Park CK; Jung YS; Kim Y; Nam SH; Kim BS; Johnson MD; Kong DS; Seol HJ; Lee JI; Joo KM; Yoon Y; Park WY; Lee J; Park PJ; Nam DH
Cancer Cell; 2015 Sep; 28(3):318-28. PubMed ID: 26373279
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
9. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
10. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
12. Treatment considerations for MGMT-unmethylated glioblastoma.
Taylor JW; Schiff D
Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
[TBL] [Abstract][Full Text] [Related]
13. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
15. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
16. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
18. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
[TBL] [Abstract][Full Text] [Related]
19. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
Zarnett OJ; Sahgal A; Gosio J; Perry J; Berger MS; Chang S; Das S
JAMA Neurol; 2015 May; 72(5):589-96. PubMed ID: 25822375
[TBL] [Abstract][Full Text] [Related]
20. Survival kinase genes present prognostic significance in glioblastoma.
Varghese RT; Liang Y; Guan T; Franck CT; Kelly DF; Sheng Z
Oncotarget; 2016 Apr; 7(15):20140-51. PubMed ID: 26956052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
